Telo Genomics Corp. (TDSGF)

Telo Genomics Corp. (TDSGF) — VMCI valuation read

TDSGF prints VMCI 31/100 inside the Healthcare sector, where the median sits at 50. The 19-point below-median delta is the cleanest single-number summary of Telo Genomics Corp.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On TDSGF, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** TDSGF trades at 20.0x earnings, 11% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 0.2x leaves covenant headroom; that is the risk line for Telo Genomics Corp. on the trailing financials.

TDSGF fell 2.4% over the trailing 7 days, with a -14.7% read on a 30-day basis.